A prospective randomized study for the effect of lanthanum carbonate on FGF23 in patients with chronic kidney disease at predialysis stage.

A prospective randomized study for the effect of lanthanum carbonate on FGF23 in patients with chronic kidney disease at predialysis stage. - Effect of lanthanum carbonate on FGF23 in patients with CKD at predialysis stage.

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000016709

Enrollment

Registered

2015-03-10

Start date

2015-06-22

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

chronic kidney disease

Interventions

lanthanum carbonate calcium carbonate

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) outpatients 2) CKD stage G4 patients ( 15 < eGFR < 29 ) 3) The patients whom Phosphate level is over 4.5 mg/dL 4) documented informed concent

Exclusion criteria

Exclusion criteria: 1) Exclusion criteria were known hypersensitivity to lanthanum carbonate and calcium carbonate, and pregnancy or lactation. 2) Any reason for ineligibility suggested by the attending doctor

Design outcomes

Primary

Measure	Time frame
FGF23 at month 1, 2, 3, 4	—

Countries

Japan

Contacts

Public ContactShokichi Naito

Kitasato University Department of Nephrology

snaito@med.kitasato-u.ac.jp042-778-8111

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026